Skip to main content
Nutrient Wise Logo Nutrient Wise
  • Features
  • Library
  • Pricing
  • FAQ
Download App

← All Ingredients

The Complete Ingredient Breakdown

Kanna

Published November 20, 2026 · Last reviewed November 20, 2026 · 6,947 words · Holding supplement companies to a cleaner and higher standard

The bottom line

Bottom Line

Taking medication? The free Nutrient Wise app warns you if Kanna interacts with what you already take — before you buy it. 5 free scans a month, no card needed.

Get it on the App Store Get it on Google Play

In this breakdown
  1. What is Kanna?
  2. What the Label Won't Tell You
  3. Primary Functions & Benefits
  4. Forms & Standardization
  5. Food Sources
  6. Who Should Take Kanna
  7. Who Should AVOID or Use Caution
  8. Recommended Dosages
  9. Timing & Administration
  10. Timeline of Effects
  11. Benefits of Taking Kanna
  12. Potential Negatives & Side Effects
  13. Deficiency Symptoms
  14. Toxicity Symptoms
  15. How Kanna Works
  16. Synergistic Supplements
  17. Interactions & What NOT to Take
  18. Quality, Testing & Adulteration
  19. Special Considerations
  20. Research Status & Evidence Quality
  21. Summary & Key Takeaways

What is Kanna?

A 25 mg capsule of Zembrin, the kanna extract tested in the controlled human trials, carries about 0.1 mg of total alkaloids. One widely sold kanna powder delivers 25 times that in a single 50 mg serving, and some products state no alkaloid content at all. That gap between the dose that was studied and the dose that is sold is the subject of this issue.

Kanna is Sceletium tortuosum, a short-lived, creeping succulent of the ice plant family (Aizoaceae) from the dry Karoo country of South Africa's Western and Northern Cape. Botanists now place it in the genus Mesembryanthemum as M. tortuosum, the classification accepted by the South African National Biodiversity Institute, though "Sceletium" survives as the trade name. The genus name refers to the leaves, which dry to a skeleton of veins around the buds in the arid summer. The flowers are 20 to 40 mm across and almost always yellow. Brendler and colleagues (Current Neuropharmacology, 2021) date the first written record to about 1660, when the Dutch commander Jan van Riebeeck noted it as a Khoi trade item, and an illustration made on Governor Simon van der Stel's 1685 expedition to Namaqualand shows the skeletonized leaves. Commercial cultivation began with trial plantings in 1996, and cultivated raw material reached the market in small quantities in 2000.

Traditionally the aerial parts are crushed, sealed in a bag, left to ferment in the sun for about 8 days and then dried into light brown fibrous clumps, which are chewed, brewed as tea, smoked or taken as snuff. San and Khoi uses recorded in the literature include easing thirst, hunger and fatigue, relieving toothache and abdominal pain, calming, and intoxication. Modern products are capsules of milled herb, standardized extracts, powders, tinctures, chewing gums and "fermented kanna."

Common Names

Kanna, channa, kougoed (Afrikaans, from "kou," to chew, and "goed," stuff, first recorded around 1830), sceletium, Mesembryanthemum tortuosum, and the trade names Zembrin and Trimesemine for two proprietary extracts. Sceletium crassicaule, a closely related species with similar alkaloids, is sometimes sold or harvested in its place (see Quality, Testing & Adulteration).

Primary Active Compounds

The psychoactive principles are mesembrine-type alkaloids, and Olatunji and colleagues (Journal of Ethnopharmacology, 2021) count 25 alkaloids in four structural classes in S. tortuosum: mesembrine, Sceletium A4, joubertiamine and tortuosamine types. The four that labs measure and extracts are standardized against are mesembrine, mesembrenone, mesembrenol and mesembranol, with Δ7-mesembrenone, epimesembranol and tortuosamine as minor contributors. Total alkaloid content in wild plants ranges from about 0.05% of dry weight to almost 3% in outlier plants, with traditionally favored "mak" (mild) types averaging about 0.2% and "trek" (strong) types about 2%, according to Brendler and colleagues. The plant also contains the phenethylamine hordenine (0.027 to 1.071 mg per gram across six commercial products tested by Appley and colleagues in 2021) and pinitol.

Key Note

The alkaloids vary in ratio as well as amount, and the ratio matters because they act on different targets. In a standard receptor panel, mesembrine was the strongest blocker of the serotonin transporter (Ki 1.4 nM), while mesembrenone also inhibited phosphodiesterase-4 (PDE4) at under 1 micromolar; PDE4 is an enzyme that breaks down the signaling molecule cyclic AMP (Harvey and colleagues, Journal of Ethnopharmacology, 2011). Zembrin is specified to be at least 60% mesembrenone plus mesembrenol and under 20% mesembrine. Many retail extracts are sold as "high mesembrine." Those are different drugs in different doses under the same plant name.

Kanna is a South African succulent with real serotonin-transporter and PDE4 activity, five small controlled trials in healthy volunteers, all of one extract at roughly 0.03 to 0.2 mg of alkaloids a day, and a retail market that mostly sells something else.

Scan any Kanna product in seconds with the free NutrientWise app: App Store · Google Play

What the Label Won't Tell You

Every controlled human study of kanna located for this issue used one extract, Zembrin, at 8 to 50 mg a day. Standardized to 0.4% total alkaloids, the usual 25 mg trial dose delivers about 0.1 mg of them, and the specification caps mesembrine below 20% of that. Nootropics Depot's FSK53 kanna, a 50 mg serving standardized to 5% alkaloids and 3% mesembrine, delivers about 2.5 mg of alkaloids and 1.5 mg of mesembrine: roughly 25 times the alkaloids in the usual trial dose and more than 75 times its mesembrine. Those multiples may be underestimates, since one LiftMode lot sold as 3% mesembrine tested at 6.1%. Swanson's 50 mg capsule of whole herb states no alkaloid content, and wild plants range from 0.05% to almost 3% alkaloids in outliers. Fermentation, marketed as the traditional route to potency, cut mesembrine from 1.33% to 0.05% in a controlled experiment. No trial located for this issue tested anything near the high-dose servings.

Primary Functions & Benefits

Kanna is marketed for mood, stress, anxiety and focus. The human evidence consists of five small randomized trials indexed in PubMed and two EEG studies published outside it, all in healthy volunteers, all using Zembrin, and three of the five indexed trials list a director of its developer, HG&H Pharmaceuticals, among their authors. A 2026 review in Planta Medica by de Jong and colleagues described the evidence as "mixed," citing small samples and "clinically irrelevant populations." No trial in people diagnosed with depression or an anxiety disorder was located.

Safety and tolerability (Nell, 2013)

Nell and colleagues (Journal of Alternative and Complementary Medicine, 2013) randomized 37 healthy adults at a Cape Town trial center to Zembrin 8 mg (12 people), 25 mg (12) or placebo (13) once daily for 3 months, between February and July 2009. No efficacy outcome was measured. Vital signs, ECGs, blood counts, chemistry and urinalysis showed no differences between groups, and headache, abdominal pain and upper respiratory infections were all more common on placebo. Some Zembrin takers wrote unsolicited diary comments about better coping with stress and sleep, which is an anecdote recorded inside a trial, not a result.

Threat circuitry in the brain (Terburg, 2013)

Terburg and colleagues (Neuropsychopharmacology, 2013) gave 16 University of Cape Town undergraduates aged 18 to 21 a single 25 mg dose of Zembrin or placebo, 5 to 9 days apart, and scanned them 2 hours later. One participant was excluded for performing at chance, leaving 15. Amygdala reactivity to fearful faces under low perceptual load was lower after Zembrin (p = 0.020), and amygdala to hypothalamus coupling was reduced during emotion matching. Participants reported no general mood change. The study was funded partly by H.L. Hall and Sons, and a co-author was the director of medical and scientific affairs at HG&H.

Cognition (Chiu, 2014)

Chiu and colleagues (Evidence-Based Complementary and Alternative Medicine, 2014; NCT01805518) ran a crossover trial in Puerto Rico: 21 healthy adults with a mean age of 54.6 took Zembrin 25 mg or placebo daily for 3 weeks, washed out for 3 weeks, then switched. Five dropped out (2 on placebo, 3 on Zembrin) and only completers were analyzed. Zembrin improved cognitive flexibility and executive function on the CNS Vital Signs battery compared with placebo; memory domains did not differ. The HAM-D depression score fell 26.9% on Zembrin against 13.8% on placebo, from baselines near 2 points out of a possible 52, and the difference was not significant. The abstract and the results section swap which of the two cognitive p values (0.022 and 0.032) belongs to which domain, a small sign of how lightly the paper was checked.

Laboratory anxiety (Reay, 2020)

Reay and colleagues (Human Psychopharmacology, 2020) ran two small between-subject experiments of a single 25 mg dose in young healthy volunteers (20 per the abstract). In study 1, a 20-minute multitasking stressor, there was no treatment effect. In study 2, a 5-minute simulated public speech, self-rated anxiety was lower in the Zembrin group at the prestress time point, before the speech began, with a treatment by time interaction on heart rate. The authors called it "the first tentative behavioral evidence."

Athletes (Hoffman, 2020)

Hoffman and colleagues (Journal of Strength and Conditioning Research, 2020) gave 60 recreationally trained adults aged 20 to 35 (48 men, 12 women) 25 mg of Sceletium extract or placebo for 8 days. Complex reactive agility under cognitive load improved; simple reaction time, alertness and energy ratings, and total mood scores on the Profile of Mood States did not. The authors concluded that "no benefits in mood were observed."

EEG studies (Dimpfel)

Two studies led by Wilfried Dimpfel, each in 60 healthy adults and summarized by Brendler and colleagues, compared Zembrin 25 mg, 50 mg and placebo. The single-dose study, in adults aged 40 to 75, reported frontal EEG changes during mental tasks. The 6-week study, in adults aged 50 to 80, reported better scores on two of six cognitive tests and a fall in the Hamilton Anxiety Rating Scale within the 50 mg group (p = 0.03), a before-and-after comparison inside one arm rather than a comparison with placebo. Neither study enrolled anxious participants.

Animal and cell findings

In Flinders Sensitive Line rats, a genetic depression model, Gericke and colleagues (2021) found that a single dose of Zembrin 50 mg per kg matched escitalopram 5 mg per kg on immobility in the forced swim test; no comparison with an antidepressant has been made in people. In a 2025 chronic stress study, only the male rats developed anhedonia and anxiety-like behavior, and in them Zembrin 12.5 mg per kg reduced both. In zebrafish larvae (2023), isolated mesembrine reproduced the extract's anxiolytic-like effect, but no single alkaloid reproduced its antidepressant-like effect. These are models, and they say nothing about dose in people.

Forms & Standardization

What separates kanna products is the amount and ratio of alkaloids per serving, and that ranges over at least two orders of magnitude.

Zembrin (the trial extract)

A water and ethanol (30:70) extract of the aerial parts of a cultivated mak-type selection, spray-dried onto maltodextrin, at a drug-to-extract ratio of about 2:1. Murbach and colleagues (Food and Chemical Toxicology, 2014) give the specification as 0.35% to 0.45% total alkaloids, with mesembrenone plus mesembrenol at least 60% and mesembrine under 20%. One batch analyzed by Gericke and colleagues (2021) was 47.9% mesembrenone, 32% mesembrenol, 13.2% mesembrine and 6.8% mesembranol. Each 25 mg trial capsule equaled about 50 mg of dried plant and about 100 micrograms of total alkaloids. Retail Zembrin products carry 25 mg per capsule or tablet, and the labels checked limit use to one a day: Doctor's Best Calm with Zembrin states a daily dose "not to exceed 25 mg," and Source Naturals directs 1 tablet daily.

High-mesembrine extracts

Trimesemine, made by Botanical Resource Holdings, is described as mesembrine-rich and has been studied only in cells. Retail powders are commonly sold by mesembrine percentage. Nootropics Depot's FSK53 is standardized to 5% total alkaloids and 3% mesembrine, with a 50 mg serving, which works out to about 2.5 mg of alkaloids and 1.5 mg of mesembrine. LiftMode sold a "Kanna Extract 3% Mesembrine," and its published certificates of analysis show how far a lot can stray from the label. A lot made in November 2019 and tested in February 2020 by a mass spectrometry unit at Stellenbosch University reported 3.6% mesembrine, and a 2019 encapsulated lot, with no lab named, reported 4.1%; neither gave any other alkaloid. A third lot, tested by the same Stellenbosch unit in June 2020 against a claim of at least 3% mesembrine and 5% alkaloids, reported 6.1% mesembrine and 8.0% total alkaloids, with mesembrenone at 1.6% and smaller amounts of mesembranol, mesembrenol, epimesembranol and Δ7-mesembrenone. At that potency a 50 mg serving carries about 3 mg of mesembrine, double what the "3%" label implies.

Ratio extracts with no alkaloid figure

Some sellers describe extracts only by a herb-to-extract ratio. Total Ingredients' "Organic Kanna Extract 10:1 Powder" listed neither an alkaloid percentage nor a serving size on the day checked. A ratio says how much plant went in, not how many alkaloids came out, and the starting plant can hold anywhere from 0.05% to almost 3%.

Whole herb

Swanson's Full Spectrum Sceletium Tortuosum capsule holds 50 mg of aerial stems and leaves, with no standardization stated. At the plant's reported range, that is somewhere between 0.025 and 1.5 mg of alkaloids.

Fermented kanna

Patnala and Kanfer (Journal of Ethnopharmacology, 2008) fermented aerial parts under controlled conditions. Over 10 days mesembrine fell from 1.33% to 0.05%, while Δ7-mesembrenone rose from below the method's quantification limit to 0.11%. Pure mesembrine in water converted the same way in sunlight but not in the dark. Sellers who advertise fermented kanna as stronger are describing a product that, in the one controlled test, lost almost all its mesembrine.

What the studies used

Every human trial located used Zembrin at 8, 25 or 50 mg a day (50 mg only in the two Dimpfel EEG studies), which is roughly 32 to 200 micrograms of total alkaloids. Brendler and colleagues cite case reports of 75 to 100 mg a day, about 300 to 400 micrograms, used in patients under psychiatric supervision; that is not a dose for anyone to choose for themselves. For South African and online supplements they calculate 1 to 13.6 mg of alkaloids a day by assuming every product, herb or extract, is 2% alkaloids; nobody has measured it. Nobody has run a trial at those amounts.

Food Sources

Kanna is not part of any ordinary diet outside its home region, so this section covers how it has been consumed.

In South Africa it is regulated as a food, according to Brendler and colleagues, and cultivated kanna has been blended into herbal beverage teas since about 2002. Stores in Namaqualand stocked the traditional fermented product until the 1990s, and healers there have used it for alcohol dependence, earning it the name "onse droë drank," our dry liquor. The same review reports a tea intake of about 500 mg of plant a day, which at 2% alkaloids would supply up to about 10 mg if fully extracted into the cup. That is about 100 times the alkaloids in a 25 mg Zembrin capsule. Traditional chewing used roughly 500 to 1,500 mg of plant a day, which at the 0.05% to 2.3% range the review uses for this calculation means 0.25 to 34.5 mg of alkaloids, and more from the rare outlier plants near 3%.

The same sources record that "minute quantities" are added to breast milk for infant colic and that a few drops of leaf juice were once given to calm young children. That is ethnography, not a safety record, and no measurement of what an infant received exists.

Where the plant grows affects what it contains. Zhao and colleagues (Phytochemistry, 2018) analyzed 289 wild samples: those from the Northern Cape held 4,938 to 9,377 mg of the four main alkaloids per kg dry weight (about 0.5% to 0.9%), while Western Cape samples averaged 16.4 to 4,143 mg per kg. Roots carry more mesembrenone and Δ7-mesembrenone and shoots more mesembrine (Faber and colleagues, 2020). Kanna has no nutritional role.

Who Should Take Kanna

No group has been shown in an adequately sized trial to benefit, and the only populations studied were healthy. The realistic candidate is a healthy adult curious about a mild effect on everyday stress who chooses a product with a stated alkaloid content near the trial range (Zembrin 25 mg, about 0.1 mg of alkaloids) and takes no serotonergic medicine.

Kanna is not a treatment for depression, an anxiety disorder or alcohol dependence. Nobody taking an antidepressant should add it, and nobody should use it to replace or taper one.

Who Should AVOID or Use Caution

Contraindications

  • Anyone taking an SSRI, SNRI, MAOI, tricyclic antidepressant or other serotonergic drug (see Interactions). Brendler and colleagues, whose author list includes Zembrin's developer, advise that antidepressants "should not be used concurrently with sceletium."

  • Pregnancy and breastfeeding. No human or animal reproductive data were located; Chiu's trial excluded pregnant women, and the Doctor's Best label says to consult a physician first. Avoid it.

  • Children and adolescents. No pediatric data exist, and the traditional infant use is undocumented in dose. Antidepressants that block serotonin reuptake carry boxed warnings about suicidal thinking in young people; kanna has never been studied for that risk.

  • Bipolar disorder or a past manic episode. This is an inference from kanna's serotonin-reuptake activity: antidepressant drugs with that mechanism can trigger mania, and no data on kanna exist either way.

  • Known allergy to kanna or ice plant family members.

Use Caution

  • Liver disease. Mesembrine and mesembrenone are cleared by liver enzymes (CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4/5 in human liver preparations), and no study in impaired liver function exists.

  • Seizure disorders. Chiu's trial excluded epilepsy. A rat slice study suggests some alkaloids damp hippocampal excitability, but serotonergic drugs can also lower seizure threshold, and no human data exist.

  • Heart disease, heart rhythm problems or uncontrolled high blood pressure. In mice, two wild chemotypes raised brain noradrenaline (Kaschula and colleagues, 2025), a 2025 computer-modeling study flagged possible heart rhythm (hERG) effects for mesembrine, and Chiu's trial excluded uncontrolled hypertension, unstable angina and recent heart attack. No human cardiovascular data exist.

  • Kidney impairment. The same modeling study predicted kidney toxicity, Chiu's trial excluded renal failure and serious kidney disease, and no study in impaired kidney function exists.

  • Driving or operating machinery. A Sceletium extract fraction caused loss of coordination in rats (Loria and colleagues, 2014), and recreational users describe intoxication. Do not drive until you know how it affects you, and not at all after a high-alkaloid serving.

  • Scheduled surgery. Doctor's Best tells users to stop 2 weeks before.

  • Use with alcohol, sedatives or stimulants (see Interactions).

  • A history of substance misuse. Kanna is sold in "legal high" markets, and Appley and colleagues (Drug Testing and Analysis, 2021) note that the UN Office on Drugs and Crime lists it among "plants of concern."

Critical Safety Point

Kanna's best-characterized action is blocking the serotonin transporter, the same target as SSRIs, and in binding assays mesembrine is more potent there than fluoxetine. Combining it with antidepressants, MAOIs or other serotonergic drugs risks serotonin toxicity, and high-mesembrine powders can deliver many times the alkaloid dose tested in people.

Recommended Dosages

No regulator has set a dose, and the only trial-tested amounts are for one extract.

Zembrin (standardized 0.4% alkaloid extract)

The trials used 8 to 50 mg once daily, most often 25 mg, which is about 0.1 mg of total alkaloids; only the two Dimpfel EEG studies used 50 mg. Retail Zembrin labels checked for this issue limit use to 25 mg a day.

Other standardized extracts

Calculate the alkaloid dose: serving size times total alkaloid percentage. A 50 mg serving at 5% is 2.5 mg, about 25 times the usual 25 mg trial dose, and lots can test above their stated strength. Nothing in the evidence supports starting there. If a product states only mesembrine, the total alkaloid content is unknown.

Whole herb and fermented kanna

Brendler and colleagues put traditional chewing at 500 to 1,500 mg of plant a day and report that the African Herbal Pharmacopoeia gives a daily total alkaloid intake of 2 to 12 mg. Without an assay of the specific lot, a capsule of milled herb cannot be translated into an alkaloid dose.

Duration

The longest human exposure studied is 3 months (Nell, 2013, safety only); the longest efficacy study is 6 weeks. No data cover longer use.

Timing & Administration

All the trials gave a single daily dose. In the fMRI study, effects were measured 2 hours after the capsule; in the athlete study, testing was 2 hours after the day 8 dose. Nootropics Depot suggests morning use with or without food. Traditional users chewed the plant and held it in the mouth, and Shikanga and colleagues (Planta Medica, 2012) found that all four main alkaloids crossed pig buccal and sublingual tissue, though less readily than intestinal tissue, where mesembrine permeated faster than the caffeine reference. Chewing gum formulations have been developed to exploit this. Smoking and snorting are recreational routes with no safety data. A high-mesembrine powder measured with a kitchen spoon is a dosing error waiting to happen; at a 50 mg serving, sellers advise a milligram scale.

Timeline of Effects

Single dose

Reduced amygdala reactivity to fearful faces appeared 2 hours after 25 mg (Terburg, 2013). Lower self-rated anxiety before a public speaking task appeared in one of two single-dose experiments (Reay, 2020); the other was null.

Days to weeks

After 8 days at 25 mg, complex reactive agility improved but mood did not (Hoffman, 2020). After 3 weeks at 25 mg, cognitive flexibility and executive function improved in completers (Chiu, 2014). After 6 weeks, the anxiety score fell within the 50 mg group, measured against its own baseline (Dimpfel, as summarized by Brendler).

Months

Three months at 8 or 25 mg showed no laboratory or ECG changes in 24 people taking Zembrin (Nell, 2013).

What counts as a fair trial

For stress at the trial dose, 3 to 6 weeks matches the studies. If nothing has changed by then, raising the dose moves into untested territory. Anyone with symptoms of depression lasting more than 2 weeks, or any thoughts of self-harm, needs a clinical assessment, not a supplement.

Benefits of Taking Kanna

The documented benefits are small and confined to healthy volunteers:

  • A single 25 mg dose of Zembrin reduced the amygdala's response to fearful faces in 15 analyzed students.

  • Three weeks at 25 mg improved two cognitive domains in a crossover trial of 21, analyzed in completers only.

  • In one of two single-dose experiments, Zembrin lowered anxiety before a stressor; in an 8-day athlete trial it did not improve mood.

  • After 6 weeks at 50 mg a day, an anxiety rating fell from baseline within the dose group in healthy older adults, in a study published outside PubMed.

  • Three months at up to 25 mg a day caused no measurable harm in 24 people.

In rodents and zebrafish, Zembrin behaved like an antidepressant and anxiolytic, and the indigenous record of use spans more than 350 years of written sources. None of it establishes a benefit at the doses most retail powders deliver.

Potential Negatives & Side Effects

In the trials

At 8 to 50 mg of Zembrin, side effects were no more frequent than on placebo. Chiu reported transient gastrointestinal discomfort in 9.5% during the Zembrin phase. Nell found headache was the most common adverse event, but more frequent on placebo. The trials were small and short, and 37 people is too few to detect a side effect that affects 1 in 50.

Beyond the trial dose

In rats, Loria and colleagues (Journal of Ethnopharmacology, 2014) found that a Sceletium extract fraction containing 1.5% mesembrine had antidepressant-like effects but also caused ataxia (loss of coordination) on the rotarod. Isolated mesembrine was analgesic without ataxia. Recreational use reports describe effects ranging from relaxation to intoxication, consistent with dose; no systematic human data at high doses were located. Gastrointestinal effects such as nausea are typical of PDE4 inhibitors (they limited the first-generation drug rolipram), and whether high kanna doses produce them has not been studied.

Hormones and oxidation, in the lab

In human adrenal cells, Trimesemine altered cortisol, aldosterone and androgen production (Swart and colleagues, 2015). In stressed rats, Zembrin 25 mg per kg lowered cortical glutathione, which the authors called a "prooxidant" effect. Neither has been studied in people.

Deficiency Symptoms

What kanna addresses

No deficiency state exists. Kanna supplies no nutrient, and its alkaloids have no known role in human physiology.

Bottom line

There is no blood test, no requirement and no symptom of going without kanna.

Toxicity Symptoms

At high intake

No published human poisoning or death attributed to kanna was located, and Brendler and colleagues reported in 2021 no severe adverse reactions or herb-drug interactions on record. That reflects how little the high-dose market has been studied. In rats, Murbach and colleagues found no adverse effects in a 14-day study at up to 5,000 mg per kg of Zembrin a day and a 90-day study at up to 600 mg per kg a day, the highest doses tested; the 90-day figure equals 2.4 mg of total alkaloids per kg. A 2025 computer-modeling study predicted an oral rat LD50 for pure mesembrine of 340 to 370 mg per kg and flagged possible respiratory, kidney and heart rhythm (hERG) effects. Those are predictions, not measurements.

The realistic acute danger in people is serotonin toxicity when kanna is combined with other serotonergic drugs. It typically develops within hours and features agitation, tremor, muscle jerks (clonus), overactive reflexes, sweating, fast heart rate, diarrhea and fever.

Signs to reduce or stop

  • Agitation, restlessness, tremor, twitching or jerking muscles, sweating or a racing heart, especially when another serotonergic drug is involved. High fever, rigidity or confusion needs emergency care; in the US, Poison Help is 1-800-222-1222.

  • Unsteadiness or poor coordination, the effect seen in rats at higher doses.

  • Nausea, abdominal discomfort or headache.

  • Worsening mood, new anxiety, or any thoughts of self-harm.

  • Elevated, racing or unusually energized mood, which may signal mania in a susceptible person.

General note

Kanna has not been tested for dependence in people. Rats showed no conditioned place preference, a common screen for reward, and Brendler and colleagues report no recorded withdrawal symptoms after chronic traditional use. Its sale in legal-high markets and its UN "plant of concern" listing are reasons not to treat that as settled.

How Kanna Works

Serotonin transporter blockade

Harvey and colleagues (2011) tested Zembrin and three purified alkaloids against a panel of drug targets. The extract blocked serotonin transporter binding with an IC50 of 4.3 micrograms per mL, and mesembrine bound the transporter with a Ki of 1.4 nM. Makolo and colleagues (Phytochemistry, 2019) describe mesembrine as a more potent serotonin transporter inhibitor than fluoxetine in binding assays. This is the same mechanism as SSRIs: more serotonin stays in the synapse.

PDE4 inhibition

PDE4 breaks down cyclic AMP inside cells, including neurons. Zembrin inhibited PDE4 with an IC50 of 8.5 micrograms per mL but not other phosphodiesterase families (Harvey, 2011). At the PDE4B subtype, mesembrenone was about 17 times more potent than mesembrine (IC50 values of 470 and 7,800 nM, as reported by Chiu and colleagues). Prescription PDE4 inhibitors include roflumilast for COPD. Terburg and colleagues framed Zembrin as a "dual" serotonin-reuptake and PDE4 inhibitor, a combination proposed but not proven to have additive antidepressant effects.

Monoamine release, possibly

Coetzee and colleagues (2015) found that Trimesemine reduced serotonin transporter expression in human astrocytes and mouse neurons, much as citalopram did, and increased vesicular monoamine transporter-2 (VMAT-2). They concluded that the high-mesembrine extract acts mainly as a monoamine-releasing agent. The extract inhibited monoamine oxidase-A only mildly. In mice given two wild chemotypes for 35 days, brain noradrenaline rose and GABA fell in every region measured (Kaschula and colleagues, 2025).

Other actions

Mesembranol and mesembrenol damped AMPA-type glutamate transmission in rat hippocampal slices (Dimpfel and colleagues, 2018). Zembrin produced an EEG signature in rats similar to that of rolipram.

Absorption and clearance

Mesembrine crossed pig intestinal tissue faster than caffeine in the lab. In mice, though, Manda and colleagues (2016) found oral bioavailability poor, with plasma levels below their method's 10 ng per mL quantification limit after oral dosing. In human liver preparations, mesembrine and mesembrenone were demethylated and hydroxylated by several cytochrome P450 enzymes, and the corresponding metabolites were found in rat urine (Meyer and colleagues, 2014). No human pharmacokinetic study exists, so how much alkaloid reaches the brain from a 25 mg capsule or a 50 mg high-mesembrine serving is unknown.

Synergistic Supplements

No controlled trial of kanna in combination with another supplement was located, so multi-ingredient "mood" and "calm" blends containing it are untested as combinations, and a proprietary blend label may not disclose how much kanna it contains. The one pairing to avoid outright is 5-HTP, L-tryptophan, St. John's wort or SAMe, which add serotonergic load (see below). A 2026 cell study by Schröder and colleagues found kanna extracts promoted bone mineralization in vitro and its authors suggested kanna as an add-on to antidepressants; that is a cell result and offers no evidence that the combination is safe in people.

Interactions & What NOT to Take

No human interaction study and no published interaction case involving kanna were located. The guidance below rests on kanna's documented serotonin-transporter, PDE4 and cytochrome P450 activity and on the drug classes' own labeling. Each item is an inference unless stated otherwise, and the inferences point toward avoiding the combinations.

SSRIs

Fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro) and fluvoxamine (Luvox) block the same transporter mesembrine blocks. Adding kanna stacks two reuptake inhibitors, which is the classic setup for serotonin toxicity. Brendler and colleagues name five of them and advise against concurrent use. A second problem: fluoxetine and paroxetine strongly inhibit CYP2D6, and fluvoxamine inhibits CYP1A2 and CYP2C19, all enzymes that clear mesembrine in liver preparations, so the SSRI could also raise alkaloid levels. Do not combine kanna with an SSRI, and do not use kanna to replace or taper one. The SSRI withdrawal syndrome is real, kanna has not been shown to prevent it, and overlapping the two during a taper is exactly the combination this section warns against.

SNRIs

Duloxetine (Cymbalta), venlafaxine (Effexor), desvenlafaxine (Pristiq), levomilnacipran (Fetzima) and milnacipran (Savella) block serotonin and noradrenaline reuptake. The serotonin concern is the same as with SSRIs, and the mouse finding that kanna chemotypes raise brain noradrenaline adds a second overlapping effect on blood pressure and heart rate. Brendler and colleagues name duloxetine and venlafaxine. Avoid the combination.

MAOIs

Phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), selegiline including the transdermal patch (Emsam), and rasagiline block the enzymes that break serotonin and other monoamines down. Combining an MAOI with a serotonin reuptake inhibitor is contraindicated in antidepressant labeling because it has caused fatal serotonin toxicity, and a substance that also releases monoamines, as Coetzee's cell study suggests kanna may, adds to the hazard. Two non-psychiatric drugs act as MAOIs too: the antibiotic linezolid (Zyvox) and intravenous methylene blue. Harmala alkaloids inhibit MAO-A as well: ayahuasca brews and Syrian rue (Peganum harmala) seeds are sold in the same "legal high" markets as kanna. Never combine kanna with any of them. Antidepressant labels require a 14-day gap after stopping an MAOI before starting an SSRI and at least 5 weeks after stopping fluoxetine before starting an MAOI. No washout has been defined for kanna; the conservative course is to borrow those intervals and to tell any prescriber about kanna use before an MAOI is started.

Other antidepressants

Tricyclics with strong serotonin effects, especially clomipramine (Anafranil) and imipramine, vortioxetine (Trintellix), vilazodone (Viibryd), trazodone and nefazodone all carry serotonergic risk. Bupropion (Wellbutrin) is not serotonergic but strongly inhibits CYP2D6 and lowers seizure threshold. Mirtazapine has a different mechanism but is still a psychiatric drug whose prescriber should know.

Other serotonergic drugs

  • Opioids with serotonergic activity: tramadol, tapentadol, meperidine, methadone and fentanyl.

  • Triptans for migraine (sumatriptan, rizatriptan and others) and ergot derivatives.

  • Dextromethorphan, the common cough suppressant.

  • Lithium.

  • Buspirone.

  • Amphetamines, MDMA, cocaine and other recreational stimulants, which release serotonin and noradrenaline.

  • Supplements: St. John's wort, 5-HTP, L-tryptophan and SAMe.

PDE4 inhibitors

Roflumilast (Daliresp) for COPD and apremilast (Otezla) for psoriasis and psoriatic arthritis inhibit the same enzyme family as mesembrenone. Brendler and colleagues flag roflumilast as a potential interaction. Combined use could add to nausea, weight loss and the psychiatric effects that PDE4 drug labeling warns about. Theophylline, a non-selective PDE inhibitor, belongs on the same caution list.

Drugs affected by shared liver enzymes

Because CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4/5 all handle kanna's alkaloids, strong inhibitors such as fluoxetine, paroxetine, bupropion, fluvoxamine, ketoconazole, clarithromycin and ritonavir could raise alkaloid levels. The clinical significance "is not yet known," in Brendler's words, and no study has tested whether kanna inhibits these enzymes in turn.

Alcohol, sedatives and stimulants

Rats given a Sceletium extract fraction (1.5% mesembrine, less than most retail powders) lost coordination, so alcohol, benzodiazepines, sleep drugs and sedating antihistamines may add impairment. One kanna product tested by Lesiak and colleagues (Forensic Science International, 2016) contained ephedrine, a stimulant banned in US dietary supplements, which is one more reason to avoid combining kanna with caffeine pills, decongestants or ADHD stimulants.

Quality, Testing & Adulteration

The alkaloid label problem

The most important quality fact is the one most labels omit: total alkaloids per serving and their ratio. A label stating "3% mesembrine" leaves total alkaloids unknown; a label stating "10:1" says nothing about alkaloids at all; a label stating "whole herb" could mean a 60-fold range. Brendler and colleagues counted more than 40 sceletium products in the NIH Dietary Supplement Label Database and wrote that standardized material with quantified total alkaloids and composition "is essential for this botanical to ensure safety, efficacy, and reproducibility."

Chemotype and origin

Northern and Western Cape plants differ in total alkaloids and in which alkaloids dominate (Zhao, 2018), and Kaschula and colleagues (2025) found that two wild chemotypes from Touwsrivier and De Rust changed mouse brain chemistry differently from a commercial extract. Hydroponic growing medium and feeding schedule also shift alkaloid levels (Faber, 2020).

Species substitution

Sceletium crassicaule shares the alkaloids used as quality markers, so a chromatographic profile alone may not tell them apart. Shikanga and colleagues (Phytochemical Analysis, 2013) used near-infrared hyperspectral imaging to separate the two species with more than 94% accuracy.

Adulteration

Lesiak and colleagues detected ephedrine in a commercially sold kanna product by mass spectrometry. Appley and colleagues found hordenine at 0.027 to 1.071 mg per gram across six commercial products, a 39-fold spread in a single side compound.

Testing and certification

None of USP, NSF or ConsumerLab has a monograph, certification category or review covering kanna that could be located. Zembrin is the only ingredient located with published batch standardization and a published toxicology study.

A credible certificate of analysis

The botanical name (Sceletium tortuosum or Mesembryanthemum tortuosum) and plant part; extract solvent and drug-to-extract ratio; HPLC or LC-MS results in percent for mesembrine, mesembrenone, mesembrenol, mesembranol and Δ7-mesembrenone, plus their total; the lab's name; heavy metals (lead, cadmium, mercury, arsenic) and microbial counts against stated limits; and a screen for undeclared stimulants such as ephedrine. Two of LiftMode's three published certificates gave mesembrine and metals but no other alkaloid; the third gave the full panel and showed double the labeled mesembrine.

Doing the math yourself

Multiply serving size by the total alkaloid percentage. If the answer is not on the label, the dose is unknown. Compare it with 0.1 mg, the alkaloid content of the 25 mg trial capsule. Be wary of "fermented" sold as stronger, of any product sold for smoking or snorting, and of labels with no warning about antidepressants. Doctor's Best's Calm with Zembrin label tells anyone taking antidepressant or anxiety medication to consult a physician first; several powder listings checked for this issue, including FSK53's, carried no such warning.

Special Considerations

Regulatory status

  • United States: kanna is not a federally controlled substance and is sold under dietary supplement rules, with no FDA premarket review of safety or efficacy. Zembrin's marketer obtained an independent conclusion of GRAS status (self-affirmed, not an FDA-reviewed GRAS notice) in February 2011 and announced US market entry in 2012. In October 2026 the Southern African Botanical Products Association, a trade association, announced self-affirmed GRAS status for kanna raw material and said it was pursuing the same for a generic extract; the dossier work was led by its co-founder Thomas Brendler, first author of the 2021 review this issue cites most. Self-affirmed GRAS means experts chosen by the applicant, here an industry body, reached the conclusion without FDA review.

  • Louisiana: R.S. 40:989.1, enacted as Act 159 of 2005 and amended in 2015, 2018 and 2023, makes it unlawful to produce, manufacture or distribute a preparation of listed "hallucinogenic plants" for human consumption, or possess one with that intent (2 to 10 years' imprisonment), and separately to possess such a preparation (up to 5 years). The list includes "Mesembryanthemum spp.," the genus to which kanna has been reassigned. The statute exempts products labeled as dietary supplements and manufactured in compliance with specified federal Food, Drug, and Cosmetic Act requirements, so compliant labeled supplements fall outside it while other kanna preparations sold for consumption may not. No court test of how it applies to kanna was located.

  • Canada: Brendler and colleagues counted 11 active natural health product licenses containing sceletium as of August 2020, 3 of them single-ingredient, and Zembrin's distributor states it holds a Health Canada license.

  • European Union: the same review concluded that kanna would be a novel food requiring authorization, fails the 15-year EU use requirement for a traditional herbal medicine registration, and that "there are no legal products containing sceletium in the European marketplace." No novel food authorization was located for this issue.

  • Australia: as of the 2021 review, kanna was not on the list of permissible ingredients for listed medicines and not included in any registered medicine.

  • South Africa: regulated as a food in its country of origin, with harvest, trade and export subject to bioprospecting and benefit-sharing permits under the National Environmental Management: Biodiversity Act of 2004.

  • No regulator located for this issue has approved kanna or any kanna extract as a medicine for depression or anxiety.

Benefit sharing

More than one indigenous community has claimed the traditional knowledge behind kanna. Under South Africa's 2004 biodiversity act and its 2019 Protection, Promotion, Development and Management of Indigenous Knowledge Act, every change of ownership of the raw material needs a material transfer and benefit-sharing agreement, and Brendler and colleagues note that much trade in indigenous biological resources remains effectively illegal because it is not yet tightly monitored. A buyer cannot easily verify whether a given product complied.

Who did the research

Three of the five PubMed-indexed trials (Nell, Terburg and Chiu) list Nigel Gericke as an author; the fMRI paper discloses that he is a director of HG&H Pharmaceuticals, the company that developed Zembrin, and that the study was partly funded by H.L. Hall and Sons. That does not make the findings wrong, but no independent trial of Zembrin and no trial of any other kanna product in people was located.

Drug testing

Mesembrine and mesembrenone metabolites were detected in rat urine with research screening methods, and the authors expect the approach to work in people (Meyer, 2014). Whether a given workplace or sports panel looks for them depends on the panel.

Research Status & Evidence Quality

Tier 1, chemistry and standardization (strongest)

Alkaloid identity, validated HPLC and LC-MS methods, chemotype variation across 289 samples, and the effect of fermentation are well documented. The weakness is that retail labels do not use these methods.

Tier 2, receptor and enzyme pharmacology

Serotonin transporter blockade and PDE4 inhibition replicated across several labs, plus monoamine release in cells. Consistent, but none of it measured at concentrations shown to reach the human brain.

Tier 3, small human trials in healthy volunteers

Five PubMed-indexed randomized trials (n = 37, 16, 21, 20 per the Reay abstract, and 60) and two 60-person EEG studies, all of Zembrin at 8 to 50 mg, durations from a single dose to 3 months, outcomes from brain imaging to agility. Positive findings are scattered across different endpoints; a direct test of mood found nothing.

Tier 4, animal and cell models

Antidepressant and anxiolytic effects in rats, zebrafish and chicks, a clean 90-day rat toxicology study, ataxia from a 1.5% mesembrine fraction, and hormonal and oxidative changes in cells and stressed rats.

Research Limitations

No trial in patients with depression or an anxiety disorder. No trial of any product other than Zembrin, and none at the 1 to 13.6 mg a day that Brendler and colleagues calculate retail products could deliver, assuming 2% alkaloids. No human pharmacokinetic data. No interaction study with any antidepressant, though that is the combination most likely to occur. No reproductive or pediatric data. The trials were small, short, mostly completer-analyzed and largely linked to the extract's developer.

Summary & Key Takeaways

Bottom Line

Kanna is a South African succulent whose alkaloids block the serotonin transporter and inhibit PDE4. Its human evidence comes from five small trials and two EEG studies in healthy volunteers, all using the Zembrin extract at about 0.03 to 0.2 mg of alkaloids a day, with modest effects on brain imaging, cognition and laboratory anxiety and no effect on mood in the one direct test. One widely sold high-mesembrine powder delivers 25 times the alkaloids in the usual trial dose per serving, unstandardized and fermented products cannot be dosed at all, and no trial supports any of them.

Key Safety Points

  • Do not combine kanna with SSRIs, SNRIs, MAOIs (including linezolid, methylene blue, ayahuasca and Syrian rue), tricyclics, tramadol, triptans, dextromethorphan, lithium, St. John's wort, 5-HTP or recreational stimulants.

  • Never use kanna to replace or taper an antidepressant, and never take it alongside one.

  • Avoid it in pregnancy, breastfeeding, childhood, adolescence and bipolar disorder.

  • Know your alkaloid dose: serving size times total alkaloid percentage, compared with the 0.1 mg trial capsule.

  • Agitation, tremor, muscle jerks, sweating and fever after combining kanna with another serotonergic drug need emergency care.

Special Note

A kanna label that gives a mesembrine percentage without total alkaloids, or a ratio without any alkaloid figure, is withholding the number that separates the studied dose from a dose 25 times higher. A brand that cites the Zembrin trials should be selling Zembrin, at the trial dose, with a warning about antidepressants.

Forwarded this, or reading it on the web? to get the next breakdown.

Researched and drafted with AI assistance. Every claim verified against primary sources and human-reviewed before publication. Last reviewed: November 14, 2026. Corrections: reply to any issue.

This issue is educational and is not medical advice. If you take an antidepressant, an MAOI, any other serotonergic or psychiatric medicine, a PDE4 inhibitor or an opioid, are pregnant or breastfeeding, or have bipolar disorder, heart, liver or kidney disease or a seizure disorder, talk to a qualified clinician before starting, stopping or changing kanna or any medication.

Get the next ingredient breakdown free

The Complete Ingredient Breakdown takes one supplement ingredient per issue: what it does, what the research shows, and what the label won't tell you. Free by email, unsubscribe anytime.

Subscribe free

Is Kanna safe? Common questions

Is Kanna safe for everyone?

Who may consider it: No group has been shown in an adequately sized trial to benefit, and the only populations studied were healthy. The realistic candidate is a healthy adult curious about a mild effect on everyday stress who chooses a product with a stated… Who should avoid it: Contraindications Anyone taking an SSRI, SNRI, MAOI, tricyclic antidepressant or other serotonergic drug (see Interactions). Brendler and colleagues, whose author list includes Zembrin's developer, advise that…

What are possible side effects of Kanna?

In the trials At 8 to 50 mg of Zembrin, side effects were no more frequent than on placebo. Chiu reported transient gastrointestinal discomfort in 9.5% during the Zembrin phase. Nell found headache was the most common adverse event, but more frequent on placebo. The trials were small and short, and 37 people is too few to detect a side effect that affects 1…

Does Kanna interact with medications or other supplements?

No human interaction study and no published interaction case involving kanna were located. The guidance below rests on kanna's documented serotonin-transporter, PDE4 and cytochrome P450 activity and on the drug classes' own labeling. Each item is an inference unless stated otherwise, and the inferences point toward avoiding the combinations. SSRIs…

New in the library
  • Jujube
  • Jewelweed
  • Isatis Root
  • Iceland Moss
  • Uranium

The Nutrient Wise app checks Kanna against the medications you take and warns you before you scan a supplement that could interact. It is free to start (5 scans a month, no card): App Store · Google Play.


Medical disclaimer: This page is informational, not medical advice. Talk to a licensed healthcare provider before starting any supplement, especially if you take medications or have a chronic condition. See our privacy policy for how we handle your data inside the app.

Privacy Policy Terms of Service Library

© Nutrient Wise. All rights reserved.